

Ref: NLL\CS\2011-1055

Dated: 14.10.2011

BY FAX / COURIER

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub. Investors Information Release

Dear Sirs,


Please find attached herewith an Investor Information release that "*NecLife gets EU – GMP Approval for its API Facility*".

This is for your information and record please.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited


Sunder Lal
Company Secretary



NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife gets European cGMP Approval for its Oral & Injectables Cephalosporins API Facility

Chandigarh, 14 October, 2011


Nectar Lifesciences Limited (NecLife), the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has touched a significant milestone by receiving European cGMP ("Current Good Manufacturing Practices") approval for its Cephalosporin APIs manufacturing facility in Derabassi, Punjab.

NecLife has today received the European cGMP compliance certification for both Oral & Injectables Cephalosporins followed by the successful inspection by the Hungarian Authority - National Institute for Quality and Organizational Development in Healthcare and Medicines, National Institute of Pharmacy (GYEMSZI-OGYI) in June 2011. The GYEMSZI-OGYI Certificate is accepted by all EU Health Authorities and by authorities of several other countries.

NecLife's API facility, Unit-II, has received this approval for oral molecules like Cefixime Trihydrate and injectable molecules viz. Cefepime Hydrochloride, Cefotaxime sodium, Ceftriaxone sodium and Cefuroxime sodium. This approval is a testimony to the high standards of quality and compliance practices put in place by the company. This approval will facilitate exports to the lucrative generic drug markets of Europe and this certification opens up lot of opportunities for Contract Manufacturing for NecLife for European customers besides factoring in the same in its own European dossiers for both oral and injectable formulations at Baddi, Himachal Pradesh, which has also been successfully inspected by European authorities and the final approval is awaited by Oct 2011 end. This makes NecLife one of the most integrated Cephalosporins manufacturers in the world.

NecLife's state-of-the-art manufacturing facilities have already received approvals from global regulatory authorities including USFDA, Japan MOH, MCC South Africa and Korean FDA. NecLife has filed 26 Drug Master Files (DMFs) in highly regulated markets and 6 Abbreviated New Drug Applications (ANDAs) in US.

For Nectar Lifesciences Limited


Sunder Lal
Company Secretary

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and Carbapenem active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 3 oral molecules and global No. 2 position in 2 sterile molecules. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, Carbapenem and other APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited


Phone: +91 172 304 7766

Fax: +91 172 507 9049

Email: dinesh.dua@neclife.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.

Nec Nectar Lifesciences Limited


Synder Lal
Company Secretary